Influenza treatment and prophylaxis with neuraminidase inhibitors: a review

References

• Estimates of deaths associated with seasonal influenza – United States, 1976–2007MMWR Morb Mortal Wkly Rep82720105933105106220134400
   PubMedGoogle Scholar
• WilliamsJM2009 update in prevention, evaluation, and outpatient treatment of influenzaCurr Med Res Opin4200925481782819207093
   PubMed Web of Science ®Google Scholar
• TreanerJJAvian influenzaMandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases7th edPhiladelphiaChurchill Livingstone201022702271
   Google Scholar
• ChengVCToKKTseHHungIFYuenKYTwo years after pandemic influenza A/2009/H1N1: what have we learned?Clin Microbiol Rev4201225222326322491771
   PubMed Web of Science ®Google Scholar
• BaoCJCuiLBZhouMHHongLGaoGFWangHLive-animal markets and influenza A (H7N9) virus infectionN Engl J Med2013368242337233923697471
   PubMed Web of Science ®Google Scholar
• BeckCRMcKenzieBCHashimABHarrisRCNguyen-Van-TamJSUniversity of Nottingham Influenza and the ImmunoCompromised (UNIIC) Study GroupInfluenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiologyJ Infect Dis201220681250125922904335
   PubMed Web of Science ®Google Scholar
• CortiDVossJGamblinSJA neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutininsScience2011333604485085621798894
   PubMed Web of Science ®Google Scholar
• LambeTSpencerAJMullarkeyCET-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic H1N1 influenza vaccine, and response to revaccination with seasonal trivalent-inactivated influenza vaccinePediatr Infect Dis J62012316e86e9122466328
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention National and Regional Level Outpatient Illness and Viral Surveillance2013 Available from: http://gis.cdc.gov/grasp/fluview/fluportaldashboard.htmlAccessed August 7, 2013
   Google Scholar
• Centers for Disease Control and Prevention Seasonal Influenza (Flu)Situation update: summary of weekly FluView Available from http://www.cdcgov/flu/weekly/summary.htmAccessed August 7, 2013
   Google Scholar
• Centers for Disease Control and Prevention Seasonal Influenza (Flu)Highly Pathogenic Avian Influenza A (H5N1) Virus Available from http://www.cdc.gov/flu/avianflu/h5n1-virus.htmAccessed August 7, 2013
   Google Scholar
• Centers for Disease Control and Prevention Seasonal Influenza (Flu)Highly Pathogenic Avian Influenza A (H5N1) in People Available from http://www.cdc.gov/flu/avianflu/h5n1-people.htmAccessed August 7, 2013
   Google Scholar
• World Health Organization InfluenzaFrequently Asked Questions on human infection caused by the avian influenza A (H7N9) virus2013 Available from http://www.who.int/influenza/human_animal_interface/faq_H7N9/en/index.htmlAccessed August 7, 2013
   Google Scholar
• KeYWangYZhangWHuangLChenZDeaths associated with avian influenza A(H7N9) virus in ChinaAnn Intern Med2013159215916023856693
   PubMed Web of Science ®Google Scholar
• GaoHNLuHZCaoBClinical findings in 111 cases of influenza A (H7N9) virus infectionN Engl J Med6132013368242277228523697469
   PubMed Web of Science ®Google Scholar
• XuCHaversFWangLMonitoring avian influenza A(H7N9) virus through national influenza-like illness surveillance, ChinaEmerg Infect Dis20131981289129223879887
   PubMed Web of Science ®Google Scholar
• KeYWangYLiuSHigh severity and fatality of human infections with avian influenza A (H7N9) infection in ChinaClin Infect Dis Epub872013
   Web of Science ®Google Scholar
• GaoRCaoBHuYHuman infection with a novel avian-origin influenza A (H7N9) virusN Engl J Med2013368201888189723577628
   PubMed Web of Science ®Google Scholar
• LeeSSWongNSLeungCCExposure to avian influenza H7N9 in farms and wet marketsLancet20133819880181523664058
   PubMed Web of Science ®Google Scholar
• TakedaMPekoszAShuckKPintoLHLambRAInfluenza a virus M2 ion channel activity is essential for efficient replication in tissue cultureJ Virol20027631391139911773413
   PubMed Web of Science ®Google Scholar
• McKimm-BreschkinJLInfluenza neuraminidase inhibitors: antiviral action and mechanisms of resistanceInfluenza Other Respi Viruses20137Suppl 12536
   PubMed Web of Science ®Google Scholar
• SchirmerPHolodniyMOseltamivir for treatment and prophylaxis of influenza infectionExpert Opin Drug Saf20098335737119355841
   PubMed Web of Science ®Google Scholar
• DeydeVMXuXBrightRASurveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwideThe Journal of Infectious Diseases2007196224925717570112
   PubMed Web of Science ®Google Scholar
• BrightRAMedinaMJXuXIncidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concernLancet200536694921175118116198766
   PubMed Web of Science ®Google Scholar
• BiotaSafety, tolerability and pharmacokinetic study of multiple doses of CS-8958 Available from: http://clinicaltrials.gov/ct2/results?term=laninamivirAccessed August 7, 2013
   Google Scholar
• DasKAntivirals targeting influenza A virusJ Med Chem201255146263627722612288
   PubMed Web of Science ®Google Scholar
• FurutaYTakahashiKShirakiKT-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infectionsAntiviral Res20098239510219428599
   PubMed Web of Science ®Google Scholar
• SamsonMPizzornoAAbedYBoivinGInfluenza virus resistance to neuraminidase inhibitorsAntiviral Res201398217418523523943
   PubMed Web of Science ®Google Scholar
• VargheseJNLaverWGColmanPMStructure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolutionNature1983303591235406843658
   PubMed Web of Science ®Google Scholar
• ColmanPMVargheseJNLaverWGStructure of the catalytic and antigenic sites in influenza virus neuraminidaseNature1983303591241446188957
   PubMed Web of Science ®Google Scholar
• IsonMGClinical use of approved influenza antivirals: therapy and prophylaxisInfluenza Other Respi Viruses20137Suppl 1713
   PubMed Web of Science ®Google Scholar
• BurmeisterWPRuigrokRWCusackSThe 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acidEMBO J199211149561740114
   PubMed Web of Science ®Google Scholar
• FengEYeDLiJRecent advances in neuraminidase inhibitor development as anti-influenza drugsChemMedChem2012791527153622807317
   PubMed Web of Science ®Google Scholar
• GongJZLiuYXuWFPharmacophore model of influenza neuraminidase inhibitors – a systematic reviewPharmazie2009641062763219947162
   PubMed Web of Science ®Google Scholar
• RussellRJHaireLFStevensDJThe structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug designNature20064437107454916915235
   PubMed Web of Science ®Google Scholar
• XuJDavisCTChristmanMCEvolutionary history and phylodynamics of influenza A and B neuraminidase (NA) genes inferred from large-scale sequence analysesPloS ONE201277e3866522808012
   PubMed Web of Science ®Google Scholar
• von ItzsteinMWuWYKokGBRational design of potent sialidase-based inhibitors of influenza virus replicationNature199336364284184238502295
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKlineRelenza: Prescribing information Available from: http://us.gsk.com/products/assets/us_relenza.pdfAccessed August 7, 2013
   Google Scholar
• KimCULewWWilliamsMAInfluenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activityJ Am Chem Soc1997119468169016526129
   PubMed Web of Science ®Google Scholar
• BeckCRSokalRArunachalamNUK Antiviral Effectiveness Review GroupNeuraminidase inhibitors for influenza: a review and public health perspective in the aftermath of the 2009 pandemicInfluenza Other Respi Viruses20137Suppl 11424
   Web of Science ®Google Scholar
• BoltzDAAldridgeJRJrWebsterRGGovorkovaEADrugs in development for influenzaDrugs201070111349136220614944
   PubMed Web of Science ®Google Scholar
• ChairatKTarningJWhiteNJPharmacokinetic properties of anti-influenza neuraminidase inhibitorsJ Clin Pharmacol201353211913923436258
   PubMed Web of Science ®Google Scholar
• KoyamaKTakahashiMNakaiNPharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in ratsXenobiotica201040320721620146556
   PubMed Web of Science ®Google Scholar
• ThorlundKAwadTBoivinGThabaneLSystematic review of influenza resistance to the neuraminidase inhibitorsBMC Infect Dis20111113421592407
   PubMed Web of Science ®Google Scholar
• FerrarisOLinaBMutations of neuraminidase implicated in neuraminidase inhibitors resistanceJ ClinVirol20084111319
   Google Scholar
• EarhartKCElsayedNMSaadMDOseltamivir resistance mutation N294S in human influenza A(H5N1) virus in EgyptJournal of Infection and Public Health200922748020701864
   PubMedGoogle Scholar
• BaranovichTWebsterRGGovorkovaEAFitness of neuraminidase inhibitor-resistant influenza A virusesCurr Opin Virol1220111657458122440915
   PubMed Web of Science ®Google Scholar
• Rameix-WeltiMAMunierSLe GalSNeuraminidase of 2007–2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitutionAntivir Ther201116459760321685548
   PubMed Web of Science ®Google Scholar
• BloomJDGongLIBaltimoreDPermissive secondary mutations enable the evolution of influenza oseltamivir resistanceScience201032859831272127520522774
   PubMed Web of Science ®Google Scholar
• VargheseJNSmithPWSollisSLDrug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidaseStructure1998667357469655825
   PubMed Web of Science ®Google Scholar
• PizzornoABouhyXAbedYBoivinGGeneration and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitorsJ Infect Dis20112031253121148493
   PubMed Web of Science ®Google Scholar
• HurtACLeeRTLeangSKIncreased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutationEuro Surveill20111623 article Id=19884
   Google Scholar
• NguyenHTFryAMLovelessPARecovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivirClin Infect Dis201051898398420858074
   PubMed Web of Science ®Google Scholar
• van der VriesEStelmaFFBoucherCAEmergence of a multidrug-resistant pandemic influenza A (H1N1) virusN Eng J Med201036313811382
   PubMed Web of Science ®Google Scholar
• SimonPHolderBPBouhyXThe I222V neuraminidase mutation has a compensatory role in replication of an oseltamivir-resistant influenza virus A/H3N2 E119V mutantJ Clin Microbiol201149271571721106781
   PubMed Web of Science ®Google Scholar
• GhedinELaplanteJDePasseJDeep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistanceJ Infect Dis2011203216817421288815
   PubMed Web of Science ®Google Scholar
• WeinstockDMGubarevaLVZuccottiGProlonged shedding of multidrug-resistant influenza A virus in an immunocompromised patientN Eng J Med20033489867868
   Web of Science ®Google Scholar
• MeijerALackenbyAHungnesOOseltamivir-resistant influenza virus A (H1N1), Europe, 2007–2008 seasonEmerg Infect Dis200915455256019331731
   PubMed Web of Science ®Google Scholar
• DharanNJGubarevaLVMeyerJJOseltamivir-Resistance Working GroupOseltamir Infections with oseltamivir-resistant influenza A (H1N1) virus in the United StatesJAMA2009301101034104119255110
   PubMed Web of Science ®Google Scholar
• LackenbyAHungnesODudmanSGEmergence of resistance to oseltamivir among influenza A(H1N1) viruses in EuropeEuro Surveill2008135 article Id=8026
   PubMedGoogle Scholar
• BazMAbedYSimonPEffect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) virusesJ Infect Dis2010201574074520100088
   PubMed Web of Science ®Google Scholar
• GovorkovaEAConsequences of resistance: in vitro fitness, in vivo infectivity, and transmissibility of oseltamivir-resistant influenza A virusesInfluenza Other Respi Viruses20137Suppl 15057
   Web of Science ®Google Scholar
• DuanSBoltzDASeilerPCompetitive transmissibility and fitness of oseltamivirsensitive and resistant pandemic influenza H1N1 viruses in ferretsInfluenza Other Respi Viruses20115Suppl 17982
   Google Scholar
• HuYLuSSongZAssociation between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistanceLancet201338198852273227923726392
   PubMed Web of Science ®Google Scholar
• Okomo-AdhiamboMSheuTGGubarevaLVAssays for monitoring susceptibility of influenza viruses to neuraminidase inhibitorsInfluenza Other Respi Viruses20137Suppl 14449
   Web of Science ®Google Scholar
• GubarevaLVWebsterRGHaydenFGDetection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assayAntiviral Res2002531476111684315
   PubMed Web of Science ®Google Scholar
• BiosystemsANA-Star Influenza Neuraminidase Inhibitor Resistance Detection Kit Available from: http://www3.appliedbiosystems.com/cms/groups/applied_markets_marketing/documents/generaldocuments/cms_042653.pdfAccessed August 7, 2013
   Google Scholar
• McKimm-BreschkinJTrivediTHampsonANeuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivirAntimicrob Agents Chemother20034772264227212821478
   PubMed Web of Science ®Google Scholar
• DuanSBoltzDALiJNovel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza a viruses by single-nucleotide polymorphism analysisAntimicrob Agents Chemother201155104718472721730113
   PubMed Web of Science ®Google Scholar
• SuzukiYSaitoRSatoIIdentification of oseltamivir resistance among pandemic and seasonal influenza A (H1N1) viruses by an His275Tyr genotyping assay using the cycling probe methodJ Clin Microbio2011491125130
   Web of Science ®Google Scholar
• DeydeVMOkomo-AdhiamboMSheuTGPyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A virusesAntiviral Res2009811162418835410
   PubMed Web of Science ®Google Scholar
• FlahertyPNatsoulisGMuralidharanOUltrasensitive detection of rare mutations using next-generation targeted resequencingNucleic Acids Res2012401e222013163
   PubMed Web of Science ®Google Scholar
• PerelsonASRongLHaydenFGCombination antiviral therapy for influenza: predictions from modeling of human infectionsJ Infect Dis2012205111642164522448006
   PubMed Web of Science ®Google Scholar
• NguyenJTHoopesJDLeMHTriple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitroPLoS ONE201052e933220179772
   PubMed Web of Science ®Google Scholar
• NguyenJTSmeeDFBarnardDLEfficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A virusesPLoS ONE201271e3100622292088
   PubMed Web of Science ®Google Scholar
• SmeeDFHurstBLWongMHEffects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in miceAntimicrob Agents Chemother201054112613319901093
   PubMed Web of Science ®Google Scholar
• TarbetEBMaekawaMFurutaYCombinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in miceAntiviral Res201294110311022429564
   PubMed Web of Science ®Google Scholar
• DuvalXvan der WerfSBlanchonTBivir Study GroupEfficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trialPLoS Med2010711e100036221072246
   PubMed Web of Science ®Google Scholar
• EscuretVCornuCBoutitieFOseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infectionsAntiviral Res201296213013722909899
   PubMed Web of Science ®Google Scholar
• HoopesJDDriebeEMKelleyETriple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virusPLoS ONE2011612e2977822220216
   PubMed Web of Science ®Google Scholar
• KimWYYoung SuhGHuhJWKorean Society of Critical Care Medicine H1N1 CollaborativeTriple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilationAntimicrob Agents Chemother201155125703570921968371
   PubMed Web of Science ®Google Scholar
• Fred Hutchinson Cancer Research CenterTCAD vs. Monotherapy for Influenza A in Immunocompromised Patients Available from: http://clinicaltrials.gov/show/NCT0867139. NLM identifier: NCT0867139Accessed August 23, 2013
   Google Scholar
• Adamas Pharmaceuticals, IncOral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects (PO206) Available from: http://clinicaltrials.gov/show/NCT0979251. NLM identifier: NCT0979251Accessed August 23, 2013
   Google Scholar
• Fred Hutchinson Cancer Research CenterTCAD vs. Monotherapy for Influenza A in Immunocompromised Patients Available from: http://clinicaltrials.gov/show/NCT0867139. NLM Identifier: NCT0867139Accessed August 23, 2013
   Google Scholar
• National Institute of Allergy and Infectious DiseasesComparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications (IRC003) Available from: http://clinicaltrials.gov/ct2/show/NCT1227967. NLM Identifier: NCT1227967Accessed August 23, 2013
   Google Scholar
• SeoSEnglundJANguyenJTCombination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokineticsAntivir Ther201318337738623264438
   PubMed Web of Science ®Google Scholar
• YamashitaMTomozawaTKakutaMCS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activityAntimicrob Agents Chemother200953118619218955520
   PubMed Web of Science ®Google Scholar
• KruegerACXuYKatiWMSynthesis of potent pyrrolidine influenza neuraminidase inhibitorsBioorg Med Chem Lett20081851692169518242993
   PubMed Web of Science ®Google Scholar
• KimJHResendeRWennekesTMechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activityScience20133406128717523429702
   PubMed Web of Science ®Google Scholar
• ChamniSDe-EknamkulWRecent progress and challenges in the discovery of new neuraminidase inhibitorsExpert Opin Ther Pat201323440942323369206
   PubMed Web of Science ®Google Scholar
• MossRBHansenCSandersRLA phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infectionJ Infect Dis2012206121844185123045618
   PubMed Web of Science ®Google Scholar
• KisoMTakahashiKSakai-TagawaYT-705 (favipiravir) activity against lethal H5N1 influenza A virusesProc Natl Acad Sci U S A2010107288288720080770
   PubMed Web of Science ®Google Scholar
• SleemanKMishinVPDeydeVMIn vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) virusesAntimicrob Agents Chemother20105462517252420350949
   PubMed Web of Science ®Google Scholar
• JacksonRJCooperKLTappendenPOseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic reviewJ Infect2011621142520950645
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention Seasonal Influtenza (Flu)Use of Antivirals Available from: http://www.cdc.gov/flu/professionals/antivirals/antiviral-use-influenza.htm#postexposureAccessed August 7, 2013
   Google Scholar
• HarperSABradleyJSEnglundJAExpert Panel of the INfectious Diseases Society of AmericaSeasonal influenza in adults and children – diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of AmericaClin Infect Dis20094881003103219281331
   PubMed Web of Science ®Google Scholar
• ReisingerKShuDCupelliLSafety and tolerability of a 6-week course of oseltamivir prophylaxis for seasonal influenza in childrenInfluenza Other Respi Viruses2013711113
   Web of Science ®Google Scholar
• BazMAbedYPapenburgJEmergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxisN Eng J Med20093612322962297
   PubMed Web of Science ®Google Scholar
• MosconaANeuraminidase inhibitors for influenzaN Engl J Med2005353131363137316192481
   PubMed Web of Science ®Google Scholar